Safety and efficacy of preoperative sphincter botulinum toxin injection on postoperative pancreatic fistula after distal pancreatectomy
- Conditions
- K86.8Other specified diseases of pancreas
- Registration Number
- DRKS00007885
- Lead Sponsor
- niversitätsklinikum Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 29
• Patients scheduled for elective distal pancreaectomy for various underlying diseases • Age equal or greater than 18 years • Written informed consent
• Creatinine clearance < 30 mL/min (estimated by Cockcroft-Gault) • Serious cardiovascular disease (e.g. myocardial infarction in the last 12 months, congestive heart failure NYHA III/IV, unstable angina pectoris) • Liver cirrhosis • ASA score > III • Immunosuppressive therapy • Pregnancy or lactation • Understanding or language problems
• Inability to comply with study and/or follow-up procedures • Known allergy or intolerability to botulinum toxin • Any condition which could result in an undue risk for the patient in the opinion of the investigator
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • Technical feasibility and success of endoscopic botulinum toxin injection in the sphincter of Oddi • Occurrence of postoperative pancreatic fistula (according to the ISGPF definition) within 30 days after the index operation • Intra-abdominal fluid collection or abscess • Re-intervention (re-laparotomy and/or CT-scan and application of drainage system) due to fluid collection, bleeding or fistula <br>
- Secondary Outcome Measures
Name Time Method • Overall postoperative morbidity (according to the Clavien-Dindo classification) • Delayed gastric emptying and postpancreatectomy hemorrhage (according to the ISGPS definitions) • Postinterventional pancreatitis • 30-day mortality • Perioperative sepsis<br>• Total intensive care unit stay • Postoperative hospital stay<br>